Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes


Creative Commons License

Hui R., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.13, sa.4, 2018 (SCI-Expanded, Scopus) identifier identifier

Özet

revision posted November 1996